RPRX vs. BGNE, ALNY, CTLT, JAZZ, HZNP, PRGO, CORT, SUPN, PCRX, and NKTR
Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics Public (HZNP), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceutical preparations" industry.
Royalty Pharma (NASDAQ:RPRX) and BeiGene (NASDAQ:BGNE) are both large-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.
Royalty Pharma has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
In the previous week, Royalty Pharma had 1 more articles in the media than BeiGene. MarketBeat recorded 9 mentions for Royalty Pharma and 8 mentions for BeiGene. BeiGene's average media sentiment score of 1.17 beat Royalty Pharma's score of 1.17 indicating that BeiGene is being referred to more favorably in the news media.
BeiGene received 224 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 69.14% of users gave BeiGene an outperform vote while only 67.96% of users gave Royalty Pharma an outperform vote.
54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 48.6% of BeiGene shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 7.4% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Royalty Pharma has a net margin of 35.70% compared to BeiGene's net margin of -28.39%. Royalty Pharma's return on equity of 22.94% beat BeiGene's return on equity.
Royalty Pharma has higher earnings, but lower revenue than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Royalty Pharma presently has a consensus target price of $46.75, suggesting a potential upside of 70.56%. BeiGene has a consensus target price of $251.93, suggesting a potential upside of 69.25%. Given Royalty Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Royalty Pharma is more favorable than BeiGene.
Summary
Royalty Pharma beats BeiGene on 12 of the 18 factors compared between the two stocks.
Get Royalty Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Royalty Pharma Competitors List
Related Companies and Tools
